Merck announces $0.81 dividend and $10 billion buyback
Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...
Merck Announces Second-Quarter 2025 Dividend and $10 Billion Share Repurchase Authorization
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...
Daily1d
Merck WELIREG gets USFDA priority review for Advanced Pheochromocytoma and Paraganglioma
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA ...
Pharmabiz1d
US FDA grants priority review status to Merck’s sNDA for Welireg to treat patients with advanced pheochromocytoma and paraganglioma
Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...
MM&M2d
Merck promotes Johanna Herrmann to SVP, global communications
Herrmann will continue in her role as chief of staff to EVP and chief communications and public affairs officer Cristal Downing.
Merck Gets FDA Priority Review of Welireg in Rare Adrenal Tumors
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its Welireg oral cancer drug in patients with rare tumors that form in and around the ...
Merck’s $8 Billion Cancer Vaccine Faces First US Jury Trial
Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical ...
Merck, Eisai See Mixed Keytruda/Lenvima Results in Phase 3 Gastroesophageal Cancer Study
Merck & Co. and Eisai reported mixed results from a late-stage study of the cancer drugs Keytruda and Lenvima in patients with certain types of gastroesophageal cancer.